InnoCare Pharma LtdInnoCare Pharma Ltd - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

If you are employed by InnoCare Pharma Ltd and you wish to licence your ESG aseessment, please contact us. This ESG score for InnoCare Pharma Ltd represents its transparency towards the UN Sustainable Development Goals. This analysis of InnoCare Pharma Ltd uses intelligence from across the web as well as from available disclosures by InnoCare Pharma Ltd.

InnoCare Pharma Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.4; made up of an environmental score of 2.3, social score of 5.0 and governance score of 3.0.

SDG Transparency Score for InnoCare Pharma Ltd 

3.4

Low Impact
0 - 3
Medium
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for InnoCare Pharma Ltd 
2.3

Environmental

5.0

Social

3.0

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
.........
1617VistaGen Therapeutics Inc
3.5
Medium
1617Yumanity Therapeutics Inc
3.5
Medium
1659InnoCare Pharma Ltd
3.4
Medium
1659Acceleron Pharma Inc
3.4
Medium
1659Annexin Pharmaceuticals AB (publ)
3.4
Medium
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does InnoCare Pharma Ltd have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd disclose current and historical energy intensity?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd report the average age of the workforce?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd disclose cybersecurity risks?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd offer flexible work?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd conduct supply chain audits?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does InnoCare Pharma Ltd conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd disclose water use targets?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did InnoCare Pharma Ltd have a product recall in the last two years?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd disclose incidents of discrimination?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has InnoCare Pharma Ltd issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd disclose parental leave metrics?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is InnoCare Pharma Ltd involved in embryonic stem cell research?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd disclose its waste policy?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd report according to TCFD requirements?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd disclose energy use targets?

LockedSign up for free to unlock

Does InnoCare Pharma Ltd disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does InnoCare Pharma Ltd have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for InnoCare Pharma Ltd
These potential risks are based on the size, segment and geographies of the company.

InnoCare Pharma Limited, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It offers Orelabrutinib (ICP-022), a Bruton's tyrosine kinase for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma, and relapsed and refractory mantle cell lymphoma. ICP-022 is in Phase II studies for patients with relapsed and refractory marginal zone lymphoma, relapsed and refractory central nervous system lymphoma, and relapsed and refractory Waldenstrom's macroglobulinemia; and in a Phase I clinical trial for follicular lymphoma patients, as well as Phase I basket trial for B-cell malignancies. The company is developing Gunagratinib( ICP-192), a pan-inhibitor of fibroblast growth factor receptor (FGFR) that is in Phase I/IIa clinical trial to define its maximum tolerated dose and/or optimal biological dose, and pharmacokinetics/ pharmacodynamics in patients with solid tumors; and ICP-105, a FGFR4 inhibitor, which is in Phase I dose escalation trial for the treatment of advanced hepatocellular carcinoma. It is also developing ICP-723, a pan-inhibitor of tropomyosin-related kinase family that is in Phase I clinical trial to treat patients with neurotrophic tyrosine receptor kinase fusion-positive cancers; and ICP-332, a small-molecule inhibitor of tyrosine kinase 2 for the treatment of various T-cell mediated autoimmune disorders, such as psoriasis, inflammatory bowel disease, and systemic lupus erythematosus. The company was incorporated in 2015 and is headquartered in Beijing, China.

Sorry!

Failed to process!